Biochemistry, Genetics and Molecular Biology
Estrogen Receptor
83%
BRCA1
83%
Single Nucleotide Polymorphism
79%
Rare Variant
62%
Allele
60%
Genetics
52%
Germline Mutation
50%
Genomics
48%
Genetic Divergence
48%
Penetrance
48%
Germline
46%
Germ Cell
46%
Genetic Predisposition
41%
PALB2
41%
FGF10
41%
Colon
41%
Gene Linkage
41%
Single-Nucleotide Polymorphism
41%
CHEK2
41%
DNA Repair
41%
CYP3A
41%
DNA Damage Response
41%
DNA Mismatch Repair
41%
BRCA2
41%
Adenomatous Polyposis Coli
41%
Steroid Biosynthesis
41%
Premenopause
41%
Steroid Metabolism
41%
Case-Control Study
36%
Genotyping
27%
Microsatellite Instability
27%
Candidate Gene
20%
Minor Allele Frequency
20%
Mendelian Randomization
20%
Missense
20%
Lifespan
20%
Gene Frequency
20%
Chromosome 15
20%
Rolandic Epilepsy
16%
Genetic Polymorphism
10%
Precursor
10%
Genetic Susceptibility
10%
Beta-Catenin
10%
Gene Repair
8%
Cell Count
8%
Endometrium
8%
Programmed Cell Death
6%
Linkage Analysis
6%
Expression Quantitative Trait Loci
6%
Pribnow Box
6%
Medicine and Dentistry
Breast Cancer
100%
Colorectal Carcinoma
91%
Cancer Risk
83%
Biological Marker
45%
Intraductal Carcinoma
41%
Clear Cell Renal Cell Carcinoma
41%
Familial Cancer
41%
Hereditary Nonpolyposis Colorectal Cancer
41%
BRCA2
41%
BRCA1
41%
Rolandic Epilepsy
41%
CYP3A
41%
Amsterdam Criteria
41%
Germ Cell
41%
DNA Mismatch Repair
41%
Nivolumab
41%
Sex Hormone
41%
Estrone
41%
Neoplasm
36%
Microsatellite Instability
30%
Radiation Therapy
29%
T Lymphocyte Receptor
27%
T Cell
27%
Diseases
25%
Recurrent Disease
20%
Quadrantectomy
20%
Cell Count
20%
Case-Control Study
20%
Etiology of Breast Cancer
20%
Hormone Determination
20%
Premenopause
20%
Steroidogenesis
20%
Steroid Metabolism
20%
Penetrance
20%
Lobular Carcinoma in Situ
18%
Uterine Cancer
16%
Immunohistochemistry
16%
Treatment Response
13%
Drive
13%
Endoscopic Biopsy
13%
T Cell Receptor
13%
Cytotoxic T-Cell
13%
Endogenous Retrovirus
13%
Cancer
12%
Surgical Margin
8%
Mastectomy
8%
Hazard Ratio
8%
Primary Tumor
8%
Adenoma
8%
Single Nucleotide Polymorphism
8%
Pharmacology, Toxicology and Pharmaceutical Science
Cediranib
41%
Glioblastoma
41%
Placebo
41%
Gefitinib
41%
Hereditary Tumor Syndrome
41%
Intraductal Carcinoma
41%
Hereditary Nonpolyposis Colorectal Cancer
41%
Recurrent Disease
20%
Breast Cancer
16%
Endometrium Cancer
16%
Endocrine Therapy
8%
Neoplasm
8%
Syndrome
8%
Primary Tumor
8%
Adenoma
8%
Colorectal Carcinoma
8%
